These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
576 related articles for article (PubMed ID: 9430587)
21. Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. Lahdenranta J; Sidman RL; Pasqualini R; Arap W FASEB J; 2007 Oct; 21(12):3272-8. PubMed ID: 17513561 [TBL] [Abstract][Full Text] [Related]
22. Combination of anti-cell adhesive synthetic Arg-Gly-Asp-Ser analogue and anticancer drug doxorubicin heightens their original antimetastatic activities. Komazawa H; Fujii H; Kojima M; Mori H; Ono M; Itoh I; Azuma I; Saiki I Oncol Res; 1995; 7(7-8):341-51. PubMed ID: 8747597 [TBL] [Abstract][Full Text] [Related]
24. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970 [TBL] [Abstract][Full Text] [Related]
25. An Integrin-Targeting RGDK-Tagged Nanocarrier: Anticancer Efficacy of Loaded Curcumin. Das K; Nimushakavi S; Chaudhuri A; Das PK ChemMedChem; 2017 May; 12(10):738-750. PubMed ID: 28403559 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice. Sordillo PP; Helson L; Lesser M Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575 [TBL] [Abstract][Full Text] [Related]
27. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Allen TM; Ahmad I; Lopes de Menezes DE; Moase EH Biochem Soc Trans; 1995 Nov; 23(4):1073-9. PubMed ID: 8654684 [No Abstract] [Full Text] [Related]
28. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor. Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464 [TBL] [Abstract][Full Text] [Related]
29. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. Curnis F; Sacchi A; Corti A J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241 [TBL] [Abstract][Full Text] [Related]
30. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492 [TBL] [Abstract][Full Text] [Related]
31. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117 [TBL] [Abstract][Full Text] [Related]
32. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy. Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068 [TBL] [Abstract][Full Text] [Related]
33. RGD-mediated delivery of small-molecule drugs. Katsamakas S; Chatzisideri T; Thysiadis S; Sarli V Future Med Chem; 2017 Apr; 9(6):579-604. PubMed ID: 28394627 [TBL] [Abstract][Full Text] [Related]
34. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Temming K; Schiffelers RM; Molema G; Kok RJ Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948 [TBL] [Abstract][Full Text] [Related]
35. Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles. Du YZ; Cai LL; Liu P; You J; Yuan H; Hu FQ Biomaterials; 2012 Dec; 33(34):8858-67. PubMed ID: 22959183 [TBL] [Abstract][Full Text] [Related]
36. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Waterhouse DN; Denyssevych T; Hudon N; Chia S; Gelmon KA; Bally MB Pharm Res; 2005 Jun; 22(6):915-22. PubMed ID: 15948035 [TBL] [Abstract][Full Text] [Related]
37. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Zitzmann S; Ehemann V; Schwab M Cancer Res; 2002 Sep; 62(18):5139-43. PubMed ID: 12234975 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737 [TBL] [Abstract][Full Text] [Related]
39. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146 [TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]